Lura may be available in the countries listed below.
Ingredient matches for Lura
Tamsulosin
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Lura in the following countries:
- Italy
International Drug Name Search
Tuesday, 26 April 2011
Wednesday, 20 April 2011
Ecox
Ecox may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Ecox
Ethambutol
Ethambutol dihydrochloride (a derivative of Ethambutol) is reported as an ingredient of Ecox in the following countries:
- Georgia
Monensin
Monensin sodium salt (a derivative of Monensin) is reported as an ingredient of Ecox in the following countries:
- South Africa
- United Kingdom
International Drug Name Search
Tuesday, 19 April 2011
Toral
Toral may be available in the countries listed below.
Ingredient matches for Toral
Ketorolac
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Toral in the following countries:
- Mexico
International Drug Name Search
Monday, 18 April 2011
Onfi
Generic Name: clobazam (Oral route)
KLOE-ba-zam
Commonly used brand name(s)
In the U.S.
- Onfi
Available Dosage Forms:
- Tablet
Therapeutic Class: Anticonvulsant
Pharmacologic Class: Benzodiazepine, Short or Intermediate Acting
Uses For Onfi
Clobazam is used to help control seizures (convulsions) that occur with Lennox-Gastaut syndrome (LGS). It works in the brain to prevent seizures. This medicine will not cure LGS and will only control seizures for as long as you continue to take it.
Clobazam is a benzodiazepine. Benzodiazepines belong to the group of medicines called central nervous system (CNS) depressants, which are medicines that slow down the nervous system.
This medicine is available only with your doctor's prescription.
Before Using Onfi
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of clobazam in children younger than 2 years of age. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of clobazam in the elderly. However, elderly patients are more likely to have age-related liver problems, which may require caution and an adjustment in the dose for patients receiving clobazam.
Pregnancy
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
Breast Feeding
Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.
Interactions with Medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
- Thioridazine
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Alfentanil
- Amobarbital
- Anileridine
- Aprobarbital
- Butabarbital
- Butalbital
- Carisoprodol
- Chloral Hydrate
- Chlorzoxazone
- Codeine
- Dantrolene
- Ethchlorvynol
- Fentanyl
- Hydrocodone
- Hydromorphone
- Levorphanol
- Meperidine
- Mephenesin
- Mephobarbital
- Meprobamate
- Metaxalone
- Methocarbamol
- Methohexital
- Morphine
- Morphine Sulfate Liposome
- Oxycodone
- Oxymorphone
- Pentobarbital
- Phenobarbital
- Primidone
- Propoxyphene
- Remifentanil
- Secobarbital
- Sodium Oxybate
- Sufentanil
- Thiopental
- Tramadol
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Dextromethorphan
- Felbamate
- Fosphenytoin
- Ginkgo
- Ketoconazole
- Phenytoin
- Theophylline
Interactions with Food/Tobacco/Alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.
- Ethanol
Other Medical Problems
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
- Alcohol abuse, history of or
- Drug abuse, history of—Dependence may be more likely to develop.
- Depression, history of or
- Mental illness, history of—Use with caution. May make these conditions worse.
- Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.
Proper Use of Onfi
Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.
This medicine comes with a Medication Guide. It is very important that you read and understand this information. Be sure to ask your doctor about anything you do not understand.
Swallow the tablet whole, or it may be crushed or mixed in an applesauce. You may take the tablet with or without food.
Dosing
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For oral dosage form (tablets):
- For seizures:
- Adults, teenagers, and children 2 years of age and older weighing 30 kg or less—Dose is based on body weight and must be determined by your doctor. The starting dose is usually 5 milligrams (mg) once a day. Your doctor may increase your dose at days 7 and 14 of treatment as needed and tolerated. However, the dose is usually not more than 20 mg per day.
- Adults, teenagers, and children 2 years of age and older weighing more than 30 kg—Dose is based on body weight and must be determined by your doctor. The starting dose is usually 10 mg per day, taken in two divided doses. Your doctor may increase your dose at days 7 and 14 of treatment as needed and tolerated. However, the dose is usually not more than 40 mg per day.
- Older adults—Dose is based on body weight and must be determined by your doctor. The starting dose is usually 5 mg per day. Your doctor may increase your dose as needed and tolerated. However, the dose is usually not more than 20 or 40 mg per day depending on weight.
- Children up to 2 years of age—Use and dose must be determined by your doctor.
- For seizures:
Missed Dose
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Storage
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Precautions While Using Onfi
It is very important that your doctor check you or your child's progress at regular visits to make sure this medicine is working properly.
This medicine will add to the effects of alcohol and other CNS depressants (medicines that make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; medicine for seizures or barbiturates; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your medical doctor or dentist before taking any of the above while you are taking this medicine.
This medicine may cause some people to become dizzy, drowsy, trouble with thinking, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert or able to think well.
Do not suddenly stop taking this medicine without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This may help prevent a possible worsening of your condition and reduce the possibility of withdrawal symptoms such as headache, nausea, irritability, tremors, or trouble sleeping.
This medicine may be habit-forming. If you feel that the medicine is not working as well, do not use more than your prescribed dose. Call your doctor for instructions.
If you or your child develop any unusual or strange thoughts and behavior while taking this medicine, be sure to discuss it with your doctor. Some changes that have occurred in people taking this medicine are like those seen in people who drink too much alcohol. Other changes might be confusion, worsening of depression, hallucinations (seeing, hearing, or feeling things that are not there), suicidal thoughts, and unusual excitement, nervousness, or irritability.
Birth control pills may not work as well while you are using this medicine. To keep from getting pregnant, use another form of birth control together with your birth control pills. Other forms include condoms, diaphragms, or contraceptive foams or jellies.
Tell your doctor if you become pregnant while taking this medicine. Your doctor may want you to join the North American Antiepileptic Drug Pregnancy Registry. The registry is used by pregnant patients who are taking this medicine.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Onfi Side Effects
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
More common
- Difficulty with swallowing
- fever
- shakiness and unsteady walk
- unsteadiness, trembling, or other problems with muscle control or coordination
- Changes in patterns and rhythms of speech
- restlessness
- slurred speech
- trouble sitting still
- trouble with speaking
- Agitation
- black, tarry stools
- bleeding gums
- blistering, peeling, or loosening of the skin
- blood in the urine or stools
- chest pain
- chills
- confusion as to time, place, or person
- cough
- diarrhea
- difficult or troubled breathing
- holding false beliefs that cannot be changed by fact
- irregular, fast or slow, or shallow breathing
- itching
- joint or muscle pain
- lack of feeling or emotion
- painful or difficult urination
- pale or blue lips, fingernails, or skin
- pinpoint red spots on the skin
- red skin lesions, often with a purple center
- red, irritated eyes
- seeing, hearing, or feeling things that are not there
- shortness of breath
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- swollen glands
- troubled breathing with exertion
- uncaring
- unusual bleeding or bruising
- unusual excitement, nervousness, or restlessness
- unusual tiredness or weakness
Get emergency help immediately if any of the following symptoms of overdose occur:
Symptoms of overdose
- change in consciousness
- confusion
- difficulty with sleeping
- disorientation
- dizziness
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- drowsiness
- drowsiness to profound coma
- loss of consciousness
- unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Attack, assault, or force
- body aches or pain
- decreased appetite
- difficulty having a bowel movement (stool)
- drooling
- ear congestion
- irritability
- loss of voice
- nasal congestion
- relaxed and calm
- runny nose
- sleepiness or unusual drowsiness
- sleeplessness
- sneezing
- unable to sleep
- vomiting
- wheezing
- Bladder pain
- bloody or cloudy urine
- cough producing mucus
- frequent urge to urinate
- increased appetite
- lower back or side pain
- Blurred vision
- double vision
- full or bloated feeling
- headache
- hives or welts
- muscle spasms
- pressure in the stomach
- rash
- redness of the skin
- sweating
- swelling of the abdominal or stomach area
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Wednesday, 13 April 2011
Citalopram Qualimed
Citalopram Qualimed may be available in the countries listed below.
Ingredient matches for Citalopram Qualimed
Citalopram
Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Citalopram Qualimed in the following countries:
- France
International Drug Name Search
Tuesday, 12 April 2011
Betapace
Generic Name: sotalol (SOE ta lol)
Brand Names: Betapace, Sorine
What is Betapace (sotalol)?
Sotalol is in a group of drugs called beta-blockers. Beta-blockers affect the heart and circulation (blood flow through arteries and veins).
Sotalol is used to help keep the heart beating normally in people with certain heart rhythm disorders of the ventricles (the lower chambers of the heart that allow blood to flow out of the heart). Sotalol is used in people with ventricular tachycardia or ventricular fibrillation.
Another form of this medicine, called Sotalol AF, is used to treat heart rhythm disorders of the atrium (the upper chambers of the heart that allow blood to flow into the heart). Sotalol AF is used in people with atrial fibrillation or atrial flutter. Sotalol (Betapace and Sorine) is not used for the same conditions that sotalol AF (Betapace AF) is used for.
Sotalol may also be used for other purposes not listed in this medication guide.
What is the most important information I should know about Betapace (sotalol)?
You will receive your first few doses of sotalol in a hospital setting where your heart rhythm can be monitored, in case the medication causes serious side effects.
If there are any changes in the brand or strength of sotalol you use, your dosage needs may change. Betapace and Sorine are not used for the same conditions that Betapace AF is used for. Always check your medicine when it is refilled to make sure you have received the correct brand and type as prescribed by your doctor. Ask the pharmacist if you have any questions about the medicine given to you at the pharmacy.
Do not skip doses or stop taking sotalol without first talking to your doctor. Stopping suddenly may make your condition worse. You may need to use less and less before you stop the medication completely.
If you need to have any type of surgery, you may need to temporarily stop using sotalol. Be sure the surgeon knows ahead of time that you are using sotalol.
What should I discuss with my healthcare provider before taking Betapace (sotalol)?
Do not use this medication if you are allergic to sotalol, or if you have:
asthma;
certain heart conditions, especially "AV block" (unless you have a pacemaker);
a history of "Long QT syndrome"; or
severe or uncontrolled congestive heart failure.
If you have any of these other conditions, you may need a dose adjustment or special tests to safely take sotalol:
breathing problems such as bronchitis or emphysema;
a history of heart disease or congestive heart failure;
diabetes;
kidney disease;
a thyroid disorder;
an electrolyte imbalance such as low levels of potassium or magnesium in your blood; or
if you have recently had a heart attack.
FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Sotalol can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
How should I take Betapace (sotalol)?
You will receive your first few doses of sotalol in a hospital setting where your heart can be monitored in case the medication causes serious side effects.
Take sotalol exactly as it was prescribed for you. Do not take the medication in larger amounts or for longer than recommended by your doctor. Follow the directions on your prescription label.
If there are any changes in the brand or strength of sotalol you use, your dosage needs may change. Betapace and Sorine are not used for the same conditions that Betapace AF is used for. Always check your medicine when it is refilled to make sure you have received the correct brand and type as prescribed by your doctor. Ask the pharmacist if you have any questions about the medicine given to you at the pharmacy.
Take this medication with a full glass of water.
Take sotalol at the same time every day.
Do not skip doses or stop taking sotalol without first talking to your doctor. Stopping suddenly may make your condition worse. You may need to use less and less before you stop the medication completely.
Tell your doctor if you have an illness that involves diarrhea or vomiting lasting more than a few hours. Prolonged diarrhea or vomiting can lower your potassium levels, making it dangerous for you to use sotalol.
To be sure this medication is helping your condition, your blood pressure will need to be checked on a regular basis. Your heart and kidney function will also need to be tested. Do not miss any scheduled visits to your doctor.
This medication can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using sotalol.
If you need to have any type of surgery, tell the surgeon that you are using sotalol. You may need to briefly stop using sotalol before having surgery.
Store sotalol at room temperature away from moisture and heat.
See also: Betapace dosage (in more detail)
What happens if I miss a dose?
Take the missed dose as soon as you remember. If your next dose is less than 8 hours away, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention if you think you have used too much of this medicine.
Overdose symptoms may include slow or fast heartbeats, shortness of breath, chest pain, swelling, hunger, weakness, confusion, sweating, feeling light-headed, fainting, or seizure (convulsions).
What should I avoid while taking Betapace (sotalol)?
Do not take an antacid within 2 hours before or after taking sotalol. Avoid using antacids without your doctor's advice. Use only the specific type of antacid your doctor recommends. Antacids contain different medicines and some types can make it harder for your body to absorb sotalol.
Betapace (sotalol) side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:
fast or pounding heartbeat, chest pain, shortness of breath;
feeling light-headed, fainting;
slow heartbeat;
unusual sweating, increased thirst; or
swelling, rapid weight gain.
Less serious side effects may include:
mild diarrhea, nausea, vomiting;
headache;
sleep problems (insomnia); or
tired feeling.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Betapace (sotalol)?
Tell your doctor about all other medications you use, especially:
clonidine (Catapres);
digoxin (digitalis, Digitek, Lanoxicaps, Lanoxin);
reserpine;
a diuretic (water pill);
drugs that can affect heart rhythm, such as cisapride (Propulsid), droperidol (Inapsine), methadone (Methadose), pentamidine (NebuPent, Pentam);
any other heart rhythm medications, especially amiodarone (Cordarone, Pacerone), dofetilide (Tikosyn), disopyramide (Norpace), procainamide (Procan), quinidine (Quinaglute, Quinidex, Quin-Release);
antibiotics such as azithromycin (Zithromax), clarithromycin (Biaxin), erythromycin (E-Mycin, E.E.S., Erythrocin, Ery-Tab), telithromycin (Ketek);
medicines to treat psychiatric disorder, such as pimozide (Orap), haloperidol (Haldol), thioridazine (Mellaril);
a phenothiazine such as chlorpromazine (Thorazine), thioridazine (Mellaril), fluphenazine (Permitil, Prolixin), perphenazine (Trilafon), prochlorperazine (Compazine), trifluoperazine (Stelazine);
an antidepressant such as amitriptyline (Elavil, Vanatrip), doxepin (Sinequan), desipramine (Norpramin), imipramine (Janimine, Tofranil), nortriptyline (Pamelor), and others;
a diabetes medication such as insulin, glyburide (Diabeta, Micronase, Glynase), glipizide (Glucotrol), chlorpropamide (Diabinese), metformin (Glucophage);
a calcium channel blocker such as diltiazem (Cartia, Cardizem), felodipine (Plendil), nifedipine (Nifedical, Procardia), verapamil (Calan, Covera, Isoptin, Verelan), and others; or
medicine for asthma other breathing disorders, such as albuterol (Ventolin, Proventil), metaproterenol (Alupent), pirbuterol (Maxair), terbutaline (Brethaire, Brethine, Bricanyl), and theophylline (Elixophyllin, Theo-24, Uniphyl).
This list is not complete and there may be other drugs that can interact with sotalol. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
More Betapace resources
- Betapace Side Effects (in more detail)
- Betapace Dosage
- Betapace Use in Pregnancy & Breastfeeding
- Drug Images
- Betapace Drug Interactions
- Betapace Support Group
- 1 Review for Betapace - Add your own review/rating
- Betapace Prescribing Information (FDA)
- Betapace Advanced Consumer (Micromedex) - Includes Dosage Information
- Betapace MedFacts Consumer Leaflet (Wolters Kluwer)
- Sotalol Prescribing Information (FDA)
- Betapace AF Prescribing Information (FDA)
- Betapace AF MedFacts Consumer Leaflet (Wolters Kluwer)
- Sorine Prescribing Information (FDA)
- Sotalol Hydrochloride Monograph (AHFS DI)
Compare Betapace with other medications
- Ventricular Arrhythmia
Where can I get more information?
- Your pharmacist can provide more information about sotalol.
See also: Betapace side effects (in more detail)
Sunday, 10 April 2011
Klorhexidinsprit
Klorhexidinsprit may be available in the countries listed below.
Ingredient matches for Klorhexidinsprit
Chlorhexidine
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Klorhexidinsprit in the following countries:
- Norway
International Drug Name Search
Saturday, 9 April 2011
Kaletra
Kaletra is a brand name of lopinavir/ritonavir, approved by the FDA in the following formulation(s):
KALETRA (lopinavir; ritonavir - capsule; oral)
Manufacturer: ABBOTT
Approval date: September 15, 2000
Strength(s): 133.3MG;33.3MG [RLD]
KALETRA (lopinavir; ritonavir - solution; oral)
Manufacturer: ABBOTT
Approval date: September 15, 2000
Strength(s): 80MG/ML;20MG/ML [RLD]
KALETRA (lopinavir; ritonavir - tablet; oral)
Manufacturer: ABBOTT
Approval date: October 28, 2005
Strength(s): 200MG;50MG [RLD]
Manufacturer: ABBOTT
Approval date: November 9, 2007
Strength(s): 100MG;25MG
Has a generic version of Kaletra been approved?
No. There is currently no therapeutically equivalent version of Kaletra available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kaletra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical composition for inhibiting HIV protease
Patent 5,484,801
Issued: January 16, 1996
Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Manning; Lourdes P. & Kaul; Dilip
Assignee(s): Abbott Laboratories
A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.Patent expiration dates:
- January 28, 2014✓
- July 28, 2014✓
- January 28, 2014
Retroviral protease inhibiting compounds
Patent 5,541,206
Issued: July 30, 1996
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
Assignee(s): Abbott Laboratories
A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.Patent expiration dates:
- July 30, 2013✓✓
- July 30, 2013✓✓✓
- July 30, 2013✓✓✓
- July 30, 2013✓✓✓
- January 30, 2014✓
- July 30, 2013
Retroviral protease inhibiting compounds
Patent 5,648,497
Issued: July 15, 1997
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Codacovi; Lynn M. & Sham; Hing L. & Wittenberger; Steven J.
Assignee(s): Abbott Laboraotries
A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.Patent expiration dates:
- July 15, 2014
- July 15, 2014✓
- July 15, 2014✓✓
- January 15, 2015✓
- July 15, 2014
Retroviral protease inhibiting compounds
Patent 5,886,036
Issued: March 23, 1999
Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
Assignee(s): Abbott Laboratories
A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.Patent expiration dates:
- November 19, 2013✓✓
- November 19, 2013✓✓✓
- May 19, 2014✓
- November 19, 2013
Retroviral protease inhibiting compounds
Patent 5,914,332
Issued: June 22, 1999
Inventor(s): Sham; Hing Leung & Norbeck; Daniel W. & Chen; Xiaoqi & Betebenner; David A.
Assignee(s): Abbott Laboratories
A compound of the formula: ##STR1## is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Patent expiration dates:
- December 13, 2015✓
- December 13, 2015✓✓✓
- December 13, 2015✓✓✓
- December 13, 2015✓✓✓
- June 13, 2016✓
- December 13, 2015
Pharmaceutical composition
Patent 5,948,436
Issued: September 7, 1999
Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Kaul; Dilip & Manning; Lourdes P.
Assignee(s): Abbott Laboratories
A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.Patent expiration dates:
- September 13, 2013✓
- March 13, 2014✓
- September 13, 2013
Method for improving pharmacokinetics
Patent 6,037,157
Issued: March 14, 2000
Inventor(s): Norbeck; Daniel W. & Kempf; Dale J. & Leonard; John M. & Bertz; Richard J.
Assignee(s): Abbott Laboratories
A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.Patent expiration dates:
- June 26, 2016✓
- June 26, 2016✓
- June 26, 2016✓
- December 26, 2016✓
- June 26, 2016
Pharmaceutical composition
Patent 6,232,333
Issued: May 15, 2001
Inventor(s): Lipari; John & Al-Razzak; Laman A. & Ghosh; Soumojeet & Gao; Rong & Kaul; Dilip
Assignee(s): Abbott Laboratories
A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Patent expiration dates:
- November 7, 2017
- May 7, 2018✓
- November 7, 2017
Retroviral protease inhibiting compounds
Patent 6,284,767
Issued: September 4, 2001
Inventor(s): Sham; Hing Leung & Norbeck; Daniel W. & Kempf; Dale J. & Chen; Xiaoqi & Betebenner; David A. & Herrin; Thomas R. & Kumar; Gondi N. & Lipari; John M. & Alani; Laman & Ghosh; Soumojeet & Gao; Rong R. & Kaul; Dilip
Assignee(s): Abbott Laboratories
A compound of the formula: ##STR1## is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Patent expiration dates:
- February 15, 2016✓✓
- February 15, 2016✓✓
- February 15, 2016✓✓
- August 15, 2016✓
- February 15, 2016
Pharmaceutical composition
Patent 6,458,818
Issued: October 1, 2002
Inventor(s): John; Lipari & Laman A.; Al-Razzak & Soumojeet; Ghosh & Rong; Gao & Dilip; Kaul
Assignee(s): Abbott Laboratories
A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Patent expiration dates:
- November 7, 2017
- May 7, 2018✓
- November 7, 2017
Pharmaceutical composition
Patent 6,521,651
Issued: February 18, 2003
Inventor(s): John; Lipari & Laman A.; Al-Razzak & Soumojeet; Ghosh & Rong; Gao & Dilip; Kaul
Assignee(s): Abbott Laboratories
A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).Patent expiration dates:
- November 7, 2017✓
- May 7, 2018✓
- November 7, 2017
Method for improving pharmacokinetics
Patent 6,703,403
Issued: March 9, 2004
Inventor(s): Daniel W.; Norbeck & Dale J.; Kempf & John M.; Leonard & Richard J.; Bertz
Assignee(s): Abbott Laboratories
A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.Patent expiration dates:
- June 26, 2016✓
- June 26, 2016✓
- June 26, 2016✓
- December 26, 2016✓
- June 26, 2016
Flavoring systems for pharmaceutical compositions and methods of making such compositions
Patent 6,911,214
Issued: June 28, 2005
Inventor(s): Alani; Laman & Gauwitz; Donald P. & Kaul; Dilip & Lipari; John M. & Ghosh; Soumojeet & Marsh; Kennan C. & Whelan; Richard H. & Petrossian; Vanik D.
Assignee(s): Abbott Laboratories
A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.Patent expiration dates:
- November 28, 2021✓✓
- May 28, 2022✓
- November 28, 2021
Pharmaceutical formulations
Patent 7,141,593
Issued: November 28, 2006
Inventor(s): Alani; Laman & Ghosh; Soumojeet
Assignee(s): Abbott Laboratories
Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.Patent expiration dates:
- May 22, 2020✓
- November 22, 2020✓
- May 22, 2020
Polymorph of a pharmaceutical
Patent 7,148,359
Issued: December 12, 2006
Inventor(s): Chemburkar; Sanjay R. & Patel; Ketan
Assignee(s): Abbott Laboratories
A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.Patent expiration dates:
- July 19, 2019✓
- January 19, 2020✓
- July 19, 2019
Solid dispersion pharamaceutical formulations
Patent 7,364,752
Issued: April 29, 2008
Inventor(s): Fort; James J. & Krill; Steven L. & Law; Devalina & Qiu; Yihong & Porter; William R. & Schmitt; Eric A.
Assignee(s): Abbott Laboratories
A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.Patent expiration dates:
- November 10, 2020✓✓
- May 10, 2021✓
- November 10, 2020
Pharmaceutical formulations
Patent 7,432,294
Issued: October 7, 2008
Inventor(s): Alani; Laman & Ghosh; Soumojeet
Assignee(s): Abbott Laboratories
Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.Patent expiration dates:
- May 22, 2020✓
- November 22, 2020✓
- May 22, 2020
Solid pharmaceutical dosage form
Patent 8,025,899
Issued: September 27, 2011
Inventor(s): Berndl; Gunther & Rosenberg; Joerg & Liepold; Bernd & Breitenbach; Joerg & Reinhold; Ulrich & Alani; Laman & Ghosh; Soumojeet
Assignee(s): Abbott Laboratories
A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Patent expiration dates:
- September 26, 2027✓
- March 26, 2028✓
- September 26, 2027
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 27, 2013 - ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
See also...
- Kaletra Consumer Information (Drugs.com)
- Kaletra Consumer Information (Wolters Kluwer)
- Kaletra Capsules Consumer Information (Wolters Kluwer)
- Kaletra Solution Consumer Information (Wolters Kluwer)
- Kaletra Consumer Information (Cerner Multum)
- Kaletra Advanced Consumer Information (Micromedex)
- Kaletra AHFS DI Monographs (ASHP)
- Lopinavir/Ritonavir Consumer Information (Wolters Kluwer)
- Lopinavir/Ritonavir Capsules Consumer Information (Wolters Kluwer)
- Lopinavir/Ritonavir Solution Consumer Information (Wolters Kluwer)
- Lopinavir and ritonavir Consumer Information (Cerner Multum)
- Lopinavir and ritonavir Advanced Consumer Information (Micromedex)
- Lopinavir and Ritonavir AHFS DI Monographs (ASHP)
Friday, 8 April 2011
Vancomycin Bidiphar
Vancomycin Bidiphar may be available in the countries listed below.
Ingredient matches for Vancomycin Bidiphar
Vancomycin
Vancomycin hydrochloride (a derivative of Vancomycin) is reported as an ingredient of Vancomycin Bidiphar in the following countries:
- Vietnam
International Drug Name Search
Fasoremin
Fasoremin may be available in the countries listed below.
Ingredient matches for Fasoremin
Sofalcone
Sofalcone is reported as an ingredient of Fasoremin in the following countries:
- Japan
International Drug Name Search
Subscribe to:
Posts (Atom)